Caris Life Sciences (CAI) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Labcorp (LH) has outperformed Caris Life Sciences (CAI) over the past year, gaining 13.2% versus a loss of 16.5%. Labcorp is the larger company by market cap ($25.48 billion vs $7.77 billion), about 3.3 times the size, while Caris Life Sciences is growing revenue faster (+97.0% vs +7.2%). On valuation, Labcorp trades at a lower forward P/E (15.9x vs 74.7x for Caris Life Sciences).
Labcorp pays a dividend yielding 0.92%, while Caris Life Sciences does not currently pay one. Labcorp converts more of its revenue into profit, with a net margin of 6.3% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | LH |
|---|---|---|
| Share price | $27.50 | $314.20 |
| Market cap | $7.77B | $25.48B |
| 1-day change | +1.48% | +0.71% |
| YTD return | +1.93% | +25.24% |
| 1-year return | -16.54% | +13.22% |
| 5-year return | — | +34.66% |
| P/E ratio (TTM) | 15.99 | 25.99 |
| Forward P/E | 74.69 | 15.86 |
| EPS (TTM) | $1.72 | $12.09 |
| Dividend yield | 0.00% | 0.92% |
| Annual dividend | $0.00 | $2.88 |
| Revenue (latest FY) | $812.03M | $13.95B |
| Revenue growth (YoY) | +96.97% | +7.25% |
| Net income (latest FY) | $-68.09M | $876.50M |
| Gross margin | — | 28.76% |
| Operating margin | 5.56% | 9.92% |
| Net margin | -8.38% | 6.28% |
| 52-week high | $33.65 | $341.80 |
| 52-week low | $14.19 | $244.52 |
| Distance from 52-week high | -18.28% | -8.07% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +5.75% | +9.54% |
| Average volume | 4.93M | 742.58K |
| Shares outstanding | 282.68M | 81.10M |
| Employees | 1,846 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Labcorp is about 3.3 times larger than Caris Life Sciences by market value ($25.48B vs $7.77B).
- LH has outperformed CAI by 29.8 percentage points over the past year.
- Labcorp trades at a higher earnings multiple (26.0x vs 16.0x trailing P/E).
- Labcorp is more profitable, keeping 6.3 cents of every revenue dollar as net income versus -8.4 cents for Caris Life Sciences.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +7.25%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
CAI vs LH FAQ
Which is bigger, Caris Life Sciences or Labcorp?
Labcorp (LH) is larger, with a market capitalization of $25.48B compared with $7.77B for Caris Life Sciences (CAI).
Which stock has performed better over the past year, CAI or LH?
LH returned +13.22% over the past 12 months, compared with -16.54% for CAI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAI or LH?
CAI has the lower trailing P/E at 16.0, versus 26.0 for LH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Caris Life Sciences or Labcorp?
Labcorp pays a dividend yielding 0.92%, while Caris Life Sciences does not currently pay a regular dividend.
Are Caris Life Sciences and Labcorp in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.